

### ONCOPRO LIQUID BIOPSY 73 Gene Panel with MSI

Extensive gene panel provides NCCN guideline recommended coverage across all major solid tumor cancer sites. Gives clinically actionable information for a personalized cancer management.

<b>Clinical Utility</b>	<ul style="list-style-type: none"> <li>• Sensitive to detect blood-borne</li> <li>• Not dependent on availability of tissue</li> <li>• DNA sequencing with the 73 genes to provide comprehensive tumor mutational profile</li> <li>• Identify all clinically relevant genetic alterations across all major cancers</li> <li>• Detects treatment options and provides therapy monitoring and management solutions</li> <li>• Detects somatic mutation in 73 genes, including oncogenes, tumor suppressor genes, and tumor alteration genes</li> <li>• Detects multiple types of genomic alterations, including copy number variation (CNV), insertions and deletions, and rearrangements</li> </ul>
<b>Patient Selection</b>	<ul style="list-style-type: none"> <li>• Solid Tumor</li> <li>• Cancer of unknown primary origin</li> <li>• Metastatic Cancer</li> <li>• Refractory or resistant cancer</li> <li>• Diagnostic purposes</li> </ul>
<b>Method</b>	Next Generation Sequencing
<b>Sample Type</b>	Submit 20 ml Whole Blood in 2 Streck tubes available from LPI. Ship immediately at 16-25°C. DO NOT REFRIGERATE OR FREEZE. OncoPro Liquid Biopsy Clinical Information Form (Form 50) is mandatory.
<b>Turn Around Time (TAT)</b>	Sample Daily by 9 am. Report 17 days

### 73 genes Plus MSI for Immunotherapy and Targeted Therapy Selection

Mutations (SNV) (73 Genes)				Indels ( 25 Genes)		Amplification (CNV) (14 Genes)		MSI
ABL1	ERBB2	KIT	RBI	APC	PTCH1	AR		BAT-25
AKT1	ERBB4	KRAS	ROS1	ARID1A	PTEN	BRAF		BAT-26
ALK	EGFR	LFP	RUN1	ATM	RBI	BRCA1		MSI-21
APC	FBXW7	MAP2K1	SETD2	BRCA1	RUNX1	BRCA2		MSI-24
AR	EGFR	MAP3K1	SMAD2	BRCA2	SETD3	ESR		MSI-27
ARID1A	FGFR3	MET	SMAD4	CDH1		ERBB2		
ATM	FGFR3	MLH1	SHARCA4	CDKN2A		FGFR1		
BRAF	FLT3	MPL	SHARCB1	CTCF		FGFR2		
BRCA1	GATA3	MTOR	SMO	EGFR		FGFR3		
BRCA2	GNA11	NAV1	SRG	EP300		KIT		
CDH1	GNAQ	NFE2L2	STK1	ERBB2		KRAS		
CDKN2A	GNAS	NOTCH1	TP53	GATA3		MET		
CSF1R	HNF1A	NPM1	VHL	JNFA1		PDGFRA		
CTCF	HNRAS	NRAS	KIT			PIK3CA		
CTNNA1	DNH1	PDGFRA	MET					
DNMT3A	DNH2	PK3CA	MLH1					
EGFR	JAK2	PIK3R1	MTOR					
EP300	JAK3	PTCH1	NOTCH1			ALK		
EPHA2	KDR	PTEN	NPM1			FGFR3		
EPHA5	KPI1	PTENH1	PDGFRA			ROS1		

### ONCOPRO PAN CANCER MONITOR

Monitor TREATMENT EFFICACY for NEWLY DIAGNOSED cancer patients. RECURRENCE MONITORING for existing cancer patients.

<b>Clinical Utility</b>	<ul style="list-style-type: none"> <li>• Simple, non-invasive blood test</li> <li>• Highly sensitive, multi-cancer, real-time monitoring for 17 different cancers</li> <li>• Predicts treatment efficacy and detects tumor recurrence more effectively and earlier than other blood markers and/or imaging alone</li> </ul>
<b>Patient Selection</b>	• Patients diagnosed with any Pan-Cancer listed cancer prior to a new course of therapy and/or follow-up
<b>Method</b>	Extraction, Sequencing
<b>Sample Type</b>	Submit 8 ml whole blood in 1 Lavender Top (EDTA) tube in sample collection kit available from LPI. Add the preservative supplied in the kit to the EDTA tube using a syringe & needle. Ship immediately at 16-25°C. DO NOT REFRIGERATE OR FREEZE. OncoPro CRC Screen Clinical Information Form (Form 20) is mandatory.
<b>Turn Around Time (TAT)</b>	Sample Daily by 9 am. Report 17 days

### Cancer Treatment Monitoring



From: Wu, Y. et al. and Yu, M. et al. (2019). Circulating tumor cell-free DNA in cancer management: an interdisciplinary update. Research Advances in Molecular Biology, 10, 49-65. © Springer, Full Copyright © 2019. Permission to reproduce or translate in whole or in part. Treatment Strategy, 100, 486-493.

- Colorectal
- Breast
- Lung
- Prostate
- Ovarian
- Endometrial
- Thyroid
- Small Intestine
- Pancreatic
- Liver
- Bladder
- Stomach
- Head and Neck
- Esophageal
- Gastric
- Renal Cell Carcinoma

Also Available  
ONCOPRO COLORECTAL CANCER MONITOR - CIRCULATING TUMOR CELLS



Regional Customer Care: 011-2668 0300  
National Reference Lab: Sector 18, Block F, Gurgaon, Haryana, India - 122 005  
www.lalpathlabs.com | @lalpathlabs



INTRODUCING  
A NEW RANGE OF TESTS  
Comprehensive Advanced Technology Solutions  
for your Cancer Diagnostic Needs

